Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody (mAb) targeting L-selectin (CD62L), a cell adhesion molecule found on circulating neutrophils that directs cell migration through chemotaxis to injury sites. Notably, Aselizumab has been associated with an increased incidence of infections and leukopenia following trauma [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Aselizumab (HuDreg-55) is a humanized IgG4 monoclonal antibody (mAb) targeting L-selectin (CD62L), a cell adhesion molecule found on circulating neutrophils that directs cell migration through chemotaxis to injury sites. Notably, Aselizumab has been associated with an increased incidence of infections and leukopenia following trauma [1] [2]. |
In vitro | Aselizumab can form dimers through disulfide linkage with the light chains of the chimeric monoclonal HuDreg-55 [1]. At concentrations ranging from 5 to 500 ng/mL and after 25 minutes of incubation, aselizumab inhibits the L-selectin-dependent adhesion of human lymphocytes to high endothelial venules in frozen lymph node sections [3]. |
In vivo | Aselizumab, administered intravenously at a single dose of 10 mg/kg in cynomolgus monkeys, exhibited an elimination half-life of 12.0 days [3]. |
Synonyms | HuDreg-55 |
Molecular Weight | N/A |
CAS No. | 395639-53-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Aselizumab 395639-53-9 HuDreg-55 inhibitor inhibit